IMS Capital Management raised its holdings in shares of Merck & Company, Inc. (NYSE:MRK) by 2.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,916 shares of the company’s stock after purchasing an additional 235 shares during the period. IMS Capital Management’s holdings in Merck & were worth $700,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Mycio Wealth Partners LLC grew its holdings in shares of Merck & by 20.9% during the first quarter. Mycio Wealth Partners LLC now owns 20,235 shares of the company’s stock valued at $1,286,000 after buying an additional 3,495 shares during the last quarter. Cubic Asset Management LLC grew its holdings in shares of Merck & by 2.3% during the first quarter. Cubic Asset Management LLC now owns 13,250 shares of the company’s stock valued at $842,000 after buying an additional 300 shares during the last quarter. Dubuque Bank & Trust Co. grew its holdings in shares of Merck & by 19.9% during the first quarter. Dubuque Bank & Trust Co. now owns 47,488 shares of the company’s stock valued at $3,017,000 after buying an additional 7,892 shares during the last quarter. Delta Asset Management LLC TN grew its holdings in shares of Merck & by 2.6% during the first quarter. Delta Asset Management LLC TN now owns 12,499 shares of the company’s stock valued at $794,000 after buying an additional 316 shares during the last quarter. Finally, Duncker Streett & Co. Inc. boosted its holdings in Merck & by 6.1% in the first quarter. Duncker Streett & Co. Inc. now owns 53,537 shares of the company’s stock worth $3,402,000 after purchasing an additional 3,091 shares during the last quarter. 72.86% of the stock is owned by institutional investors and hedge funds.

MRK has been the topic of several research reports. Jefferies Group LLC restated a “sell” rating and issued a $52.00 target price on shares of Merck & in a report on Sunday, August 20th. BMO Capital Markets restated a “buy” rating and issued a $72.00 target price on shares of Merck & in a report on Friday, September 8th. Credit Suisse Group dropped their target price on shares of Merck & from $75.00 to $74.00 and set an “outperform” rating on the stock in a report on Wednesday, August 30th. BidaskClub downgraded shares of Merck & from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Cowen and Company reiterated a “hold” rating and issued a $70.00 price target on shares of Merck & in a research report on Friday, September 1st. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $67.07.

COPYRIGHT VIOLATION WARNING: “IMS Capital Management Has $700,000 Holdings in Merck & Company, Inc. (MRK)” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/ims-capital-management-has-700000-holdings-in-merck-company-inc-mrk/1677207.html.

Shares of Merck & Company, Inc. (NYSE:MRK) opened at $56.06 on Friday. The stock has a market cap of $151.45 billion, a PE ratio of 14.23, a PEG ratio of 2.38 and a beta of 0.78. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.21 and a current ratio of 1.50.

Merck & (NYSE:MRK) last posted its quarterly earnings results on Friday, October 27th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $1.03 by $0.08. Merck & had a net margin of 11.60% and a return on equity of 26.82%. The business had revenue of $10.33 billion during the quarter, compared to analyst estimates of $10.54 billion. During the same quarter in the previous year, the business posted $1.07 EPS. The company’s quarterly revenue was down 2.0% compared to the same quarter last year. analysts anticipate that Merck & Company, Inc. will post 3.95 EPS for the current year.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.